Analyzing serum tryptophan metabolites in patients with gestational diabetes mellitus

1 Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. Int J Tryptophan Res. 2017;10:1178646917691938. DOI: 10.1177/1178646917691938 Search in Google Scholar

2 Oxenkrug GF. Role of Kynurenine Pathway in Insulin Resistance: Toward Kynurenine Hypothesis of Insulin Resistance and Diabetes. In: Mittal S, editor. Targeting the Broadly Pathogenic Kynurenine Pathway. Cham: Springer International Publishing; 2015. p. 169-78. DOI: 10.1007/978-3-319-11870-3_13 Search in Google Scholar

3 Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity (Silver Spring). 2015;23(10):2066-74. DOI: 10.1002/oby.21199 Search in Google Scholar

4 Marszalek-Grabska M, Walczak K, Gawel K, Wicha-Komsta K, Wnorowska S, Wnorowski A, et al. Kynurenine emerges from the shadows - Current knowledge on its fate and function. Pharmacology & Therapeutics. 2021;225:107845. DOI: 10.1016/j. pharmthera.2021.107845 Search in Google Scholar

5 Wang W, Huang L, Jin JY, Jolly S, Zang Y, Wu H, et al. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients. Cancer Res. 2018;78(3):809-16. DOI: 10.1158/0008-5472.CAN-17-2995 Search in Google Scholar

6 Duncan BB, Castilhos CD, Bracco PA, Schmidt MI, Kang S, Im S, et al. Aryl-hydrocarbon receptor binding and the incidence of type 2 diabetes: the Brazilian Longitudinal Study of Adult Health (ELSABrasil). Environ Health. 2020;19(1):105. DOI: 10.1186/s12940-020-00658-y Search in Google Scholar

7 Diabetes-Care. Proceedings of the 4th International Workshop-Conference on Gestational Diabetes Mellitus. Chicago, Illinois, USA. 14-16 March 1997. Diabetes Care. 1998;21 Suppl 2:B1-167. Search in Google Scholar

8 Angueira AR, Ludvik AE, Reddy TE, Wicksteed B, Lowe WL, Jr., Layden BT. New Insights Into Gestational Glucose Metabolism: Lessons Learned From 21st Century Approaches. Diabetes. 2015;64(2):327-34. DOI: 10.2337/db14-0877 Search in Google Scholar

9 López-Hernández Y, Herrera-Van Oostdam AS, Toro-Ortiz JC, López JA, Salgado-Bustamante M, Murgu M, et al. Urinary Metabolites Altered during the Third Trimester in Pregnancies Complicated by Gestational Diabetes Mellitus: Relationship with Potential Upcoming Metabolic Disorders. Int J Mol Sci. 2019;20(5). DOI: 10.3390/ijms20051186 Search in Google Scholar

10 Broekhuizen M, Danser AHJ, Reiss IKM, Merkus D. The Function of the Kynurenine Pathway in the Placenta: A Novel Pharmacotherapeutic Target? Int J Environ Res Public Health. 2021;18(21). DOI: 10.3390/ijerph182111545 Search in Google Scholar

11 Oxenkrug GF. Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophankynurenine metabolism. Ann N Y Acad Sci. 2010;1199:1-14. DOI: 10.1111/j.1749-6632.2009.05356.x Search in Google Scholar

12 Khambule L, George JA. The Role of Inflammation in the Development of GDM and the Use of Markers of Inflammation in GDM Screening. Adv Exp Med Biol. 2019;1134:217-42. DOI: 10.1007/978-3-030-12668-1_12 Search in Google Scholar

13 Kozieł K, Urbanska EM. Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target? Cells. 2023;12(3). DOI: 10.3390/cells12030460 Search in Google Scholar

14 Shen H, Xu X, Bai Y, Wang X, Wu Y, Zhong J, et al. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases. European Journal of Medicinal Chemistry. 2023;251:115258. DOI: 10.1016/j.ejmech.2023.115258 Search in Google Scholar

15 Kubacka J, Staniszewska M, Sadok I, Sypniewska G, Stefanska A. The Kynurenine Pathway in Obese Middle-Aged Women with Normoglycemia and Type 2 Diabetes. Metabolites. 2022;12(6). DOI: 10.3390/metabo12060492 Search in Google Scholar

16 Li Z, Geng YN, Jiang JD, Kong WJ. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evid Based Complement Alternat Med. 2014;2014:289264. DOI: 10.1155/2014/289264 Search in Google Scholar

17 Yu CJ, Zheng MF, Kuang CX, Huang WD, Yang Q. Oren-gedokuto and its constituents with therapeutic potential in Alzheimer’s disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. J Alzheimers Dis. 2010;22(1):257-66. DOI: 10.3233/JAD-2010-100684 Search in Google Scholar

18 Türkiye-Endokrinoloji-ve-Metabolizma-Derneği. DİABETES MELLİTUS VE KOMPLİKASYONLARININ TANI, TEDAVİ VE İZLEM KILAVUZU 2022. 2022. p. 227. Search in Google Scholar

19 Tong Q, Song J, Yang G, Fan L, Xiong W, Fang J. Simultaneous determination of tryptophan, kynurenine, kynurenic acid, xanthurenic acid and 5-hydroxytryptamine in human plasma by LC-MS/MS and its application to acute myocardial infarction monitoring. Biomed Chromatogr. 2018;32(4). DOI: 10.1002/bmc.4156 Search in Google Scholar

20 Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-50. DOI: 10.1016/j.diabres.2014.04.006 Search in Google Scholar

21 Oxenkrug GF. Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. Mol Neurobiol. 2015;52(2):805-10. DOI: 10.1007/s12035-015-9232-0 Search in Google Scholar

22 Oxenkrug G. Insulin resistance and dysregulation of tryptophankynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Molecular neurobiology. 2013;48(2):294-301. DOI: 10.1007/s12035-013-8497-4 Search in Google Scholar

23 Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther. 2005;7(6):R1254-62. DOI: 10.1186/ar1821 Search in Google Scholar

24 Paul L, Ueland PM, Selhub J. Mechanistic perspective on the relationship between pyridoxal 5’-phosphate and inflammation. Nutr Rev. 2013;71(4):239-44. DOI: 10.1111/nure.12014 Search in Google Scholar

25 Fallarino F, Bianchi R, Orabona C, Vacca C, Belladonna ML, Fioretti MC, et al. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med. 2004;200(8):1051-62. DOI: 10.1084/jem.20040942 Search in Google Scholar

26 Mondanelli G, Albini E, Pallotta MT, Volpi C, Chatenoud L, Kuhn C, et al. The Proteasome Inhibitor Bortezomib Controls Indoleamine 2,3-Dioxygenase 1 Breakdown and Restores Immune Regulation in Autoimmune Diabetes. Front Immunol. 2017;8:428. DOI: 10.3389/fimmu.2017.00428 Search in Google Scholar

27 Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes. 2002;51(2):356-65. DOI: 10.2337/diabetes.51.2.356 Search in Google Scholar

28 Fallarino F, Luca G, Calvitti M, Mancuso F, Nastruzzi C, Fioretti MC, et al. Therapy of experimental type 1 diabetes by isolated Sertoli cell xenografts alone. J Exp Med. 2009;206(11):2511-26. DOI: 10.1084/jem.20090134 Search in Google Scholar

29 Piras C, Neri I, Pintus R, Noto A, Petrella E, Monari F, et al. First trimester metabolomics 1H-NMR study of the urinary profile predicts gestational diabetes mellitus development in obese women. J Matern Fetal Neonatal Med. 2022;35(25):8275-83. DOI: 10.1080/14767058.2021.1970133 Search in Google Scholar

30 Yu E, Papandreou C, Ruiz-Canela M, Guasch-Ferre M, Clish CB, Dennis C, et al. Association of Tryptophan Metabolites with Incident Type 2 Diabetes in the PREDIMED Trial: A Case-Cohort Study. Clin Chem. 2018;64(8):1211-20. DOI: 10.1373/clinchem.2018.288720 Search in Google Scholar

31 Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, et al. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J. 2013;34(34):2689-96. DOI: 10.1093/eurheartj/eht264 Search in Google Scholar

32 Rebnord EW, Strand E, Midttun Ø, Svingen GFT, Christensen MHE, Ueland PM, et al. The kynurenine:tryptophan ratio as a predictor of incident type 2 diabetes mellitus in individuals with coronary artery disease. Diabetologia. 2017;60(9):1712-21. DOI: 10.1007/s00125-017-4329-9 Search in Google Scholar

33 Theofylaktopoulou D, Midttun Ø, Ulvik A, Ueland PM, Tell GS, Vollset SE, et al. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173(1):121-30. DOI: 10.1111/cei.12092 Search in Google Scholar

34 Watts SW, Shaw S, Burnett R, Dorrance AM. Indoleamine 2,3-diooxygenase in periaortic fat: mechanisms of inhibition of contraction. Am J Physiol Heart Circ Physiol. 2011;301(4):H1236-47. DOI: 10.1152/ajpheart.00384.2011 Search in Google Scholar

35 Scarpellini E, Tack J. Obesity and metabolic syndrome: an inflammatory condition. Dig Dis. 2012;30(2):148-53. DOI: 10.1159/000336664 Search in Google Scholar

36 Oxenkrug G, van der Hart M, Roeser J, Summergrad P. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients. Integr Clin Med. 2017;1(1). DOI: 10.15761/ICM.1000105 Search in Google Scholar

37 Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21(19):7463-73. DOI: 10.1523/JNEUROSCI.21-19-07463.2001 Search in Google Scholar

38 Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52(4):1319-28. DOI: 10.1111/j.1471-4159.1989.tb01881.x Search in Google Scholar

39 Catalano PM, McIntyre HD, Cruickshank JK, McCance DR, Dyer AR, Metzger BE, et al. The hyperglycemia and adverse pregnancy outcome study: associations of GDM and obesity with pregnancy outcomes. Diabetes Care. 2012;35(4):780-6. DOI: 10.2337/dc11-1790 Search in Google Scholar

40 Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis. Bmj. 2022;377:e067946. DOI: 10.1136/bmj-2021-067946 Search in Google Scholar

41 Nilsen RM, Bjørke-Monsen A-L, Midttun O, Nygård O, Pedersen ER, Ulvik A, et al. Maternal tryptophan and kynurenine pathway metabolites and risk of preeclampsia. Obstetrics and gynecology. 2012;119(6):1243-50. DOI: 10.1097/AOG.0b013e318255004e Search in Google Scholar

42 Noto Y, Okamoto H. Inhibition by kynurenine metabolites of proinsulin synthesis in isolated pancreatic islets. Acta Diabetol Lat. 1978;15(5-6):273-82. DOI: 10.1007/BF02590750 Search in Google Scholar

43 Bennink HJTC, Schreurs WHP, Bennink HJTC, Schreurs WHP. Improvement Of Oral Glucose Tolerance In Gestational Diabetes By Pyridoxine. The British Medical Journal. 1975;3(5974):13-5. DOI: 10.1136/bmj.3.5974.13 Search in Google Scholar

44 Gillmer MD, Mazibuko D. Pyridoxine treatment of chemical diabetes in pregnancy. Am J Obstet Gynecol. 1979;133(5):499-502. DOI: 10.1016/0002-9378(79)90283-7 Search in Google Scholar

45 Guillemin GJ. Quinolinic acid, the inescapable neurotoxin. Febs j. 2012;279(8):1356-65. DOI: 10.1111/j.1742-4658.2012.08485.x Search in Google Scholar